Tarsus Pharmaceuticals (TARS) EBIT Margin (2021 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly EBIT Margin came in at 3.78% in Q1 2026, up 2977.0% year-on-year from 0.12% in Q1 2025, and up 28.16% quarter-over-quarter from 5.26% in Q4 2025.
Tarsus Pharmaceuticals (TARS) EBIT Margin (2021 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' EBIT Margin history runs 6 years deep, the most recent figure standing at 3.78% for Q1 2026.
- On a quarterly basis, EBIT Margin rose 2977.0% year-over-year to 3.78% in Q1 2026; TTM through Mar 2026 was 9.5%, a 3722.0% increase from a year earlier, with the FY2025 full-year figure at 15.72%, up 5018.0% from the prior year.
- EBIT Margin advanced to 3.78% in Q1 2026 per TARS's latest filing, from 5.26% in the prior quarter.
- Across five years, EBIT Margin topped out at 3.78% in Q1 2026 and bottomed at 3621.71% in Q1 2022.
- The 5-year median for EBIT Margin is 52.29% (2024), against an average of 514.4%.
- Biggest YoY gain for EBIT Margin was 412395 bps in 2022; the steepest drop was 365375 bps in 2022.
- Year by year, EBIT Margin stood at 150.61% in 2022, then sank by 126 bps to 339.94% in 2023, then surged by 89 bps to 36.77% in 2024, then jumped by 86 bps to 5.26% in 2025, then grew by 28 bps to 3.78% in 2026.
- Per Business Quant, the three latest TARS EBIT Margin figures stand at 3.78% (Q1 2026), 5.26% (Q4 2025), and 12.24% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | -3.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.78% |
| Dec 31, 2025 | -5.26% |
| Sep 30, 2025 | -12.24% |
| Jun 30, 2025 | -21.61% |
| Mar 31, 2025 | -33.55% |
| Dec 31, 2024 | -36.77% |
| Sep 30, 2024 | -52.29% |
| Jun 30, 2024 | -81.60% |
| Mar 31, 2024 | -136.47% |
| Dec 31, 2023 | -339.94% |
| Sep 30, 2023 | -2,187.87% |
| Mar 31, 2023 | -998.08% |
| Dec 31, 2022 | -150.61% |
| Jun 30, 2022 | -34.20% |
| Mar 31, 2022 | -3,621.71% |
| Dec 31, 2021 | -4,274.56% |
| Sep 30, 2021 | -1,266.53% |
| Jun 30, 2021 | 33.07% |
| Mar 31, 2021 | 32.05% |